Saskia Ingen-Housz-Oro, Ilaria Matei, Antoine Gaillet, Julie Gueudry, Karim Zaghbib, Haudrey Assier, Pierre Wolkenstein, Nicolas de Prost
{"title":"Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023.","authors":"Saskia Ingen-Housz-Oro, Ilaria Matei, Antoine Gaillet, Julie Gueudry, Karim Zaghbib, Haudrey Assier, Pierre Wolkenstein, Nicolas de Prost","doi":"10.1016/j.jid.2024.06.1295","DOIUrl":null,"url":null,"abstract":"<p><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening reactions associated with long-term disabling sequelae. In the acute phase, the best supportive care in expert centers is the cornerstone of treatment. The follow-up is prolonged and multidisciplinary, according to the patient's needs. In this paper, we review the evidence from 2017 to 2023 for the diagnosis and management of SJS/TEN in adults. On the basis of this review and our own experience, we present recommendations for the diagnosis of SJS/TEN in adults, management in the acute phase (best supportive care; prevention of infections; skin, ocular, and other mucosa management; intensive care measures; and etiological treatment), and follow-up. The most frequent sequelae are cutaneous, ocular, and psychological. High-quality studies assessing the efficacy of immunomodulating agents (eg, cyclosporine, corticosteroids, intravenous Igs, and anti-TNF agents) in accelerating healing and reducing mortality are still lacking. In addition, we propose avenues for future studies.</p>","PeriodicalId":94239,"journal":{"name":"The Journal of investigative dermatology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of investigative dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jid.2024.06.1295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening reactions associated with long-term disabling sequelae. In the acute phase, the best supportive care in expert centers is the cornerstone of treatment. The follow-up is prolonged and multidisciplinary, according to the patient's needs. In this paper, we review the evidence from 2017 to 2023 for the diagnosis and management of SJS/TEN in adults. On the basis of this review and our own experience, we present recommendations for the diagnosis of SJS/TEN in adults, management in the acute phase (best supportive care; prevention of infections; skin, ocular, and other mucosa management; intensive care measures; and etiological treatment), and follow-up. The most frequent sequelae are cutaneous, ocular, and psychological. High-quality studies assessing the efficacy of immunomodulating agents (eg, cyclosporine, corticosteroids, intravenous Igs, and anti-TNF agents) in accelerating healing and reducing mortality are still lacking. In addition, we propose avenues for future studies.